Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Infections

Risks factors and timing of genital human papillomavirus (HPV) infection in female stem cell transplant survivors: a longitudinal study

Abstract

This longitudinal single-center study describes the timing and risk factors for genital human papillomavirus (HPV) disease in women after allogeneic hematopoietic cell transplantation (HCT). Between 1994 and 2014, 109 females underwent HCT of whom 82 surviving transplant for >1 year had regular, comprehensive genital tract assessment and treatment of HPV disease. The cumulative proportions of any genital HPV infection at 1, 3, 5, 10 and 20 years were 4.8%, 14.9%, 28.1%, 36.7% and 40.9%, respectively. Demographic, disease-related factors, chronic GvHD (cGvHD) and its treatment were analyzed for their association with persistent, multifocal or severe genital HPV disease. Pre-transplant HPV disease was strongly associated with any posttransplant HPV (odds ratio (OR)=6.5, 95% confidence interval (CI)=1.65–25.85, P=0.008). Having either extensive or genital cGvHD was associated with increased risk of any HPV disease (OR=5.7, 95% CI=1.90–17.16, P=0.002) and a higher risk for severe genital dysplasia (CIN II–III/VIN II–III; OR=13.1, 95% CI=1.59–108.26, P=0.017), but no one developed HPV-related genital cancer. Persistent, multifocal or severe HPV disease occurred more frequently than in healthy populations. Women with extensive cGvHD, genital cGvHD or pre-transplant HPV are at greatest risk for post-transplant HPV disease. Early initiation of annual screening, comprehensive genital tract assessment and active management are cornerstones of their gynecology care.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S . Human papillomavirus and cervical cancer. Lancet 2007; 370: 890–907.

    Article  CAS  Google Scholar 

  2. Schiffman M, Wentzensen N . From human papillomavirus to cervical cancer. Obstet Gynecol 2010; 116: 177–185.

    Article  Google Scholar 

  3. Trottier H, Franco EL . The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24 (Suppl 1): S1–15.

    PubMed  Google Scholar 

  4. Parkin DM, Bray F . Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24 (Supplement 3): S11–S25.

    Article  Google Scholar 

  5. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607–615.

    Article  Google Scholar 

  6. Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst 2015; 107: djv086.

    Article  Google Scholar 

  7. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003; 95: 1336–1343.

    Article  Google Scholar 

  8. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS . Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 123–137.

    Article  Google Scholar 

  9. Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158: 486–494.

    Article  Google Scholar 

  10. Doorbar J . Latent papillomavirus infections and their regulation. Curr Opin Virol 2013; 3: 416–421.

    Article  CAS  Google Scholar 

  11. Savani BN, Stratton P, Shenoy A, Kozanas E, Goodman S, Barrett AJ . Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation—implications for screening and HPV vaccination. Biol Blood Marrow Transplant 2008; 14: 1072–1075.

    Article  Google Scholar 

  12. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29: 2230–2239.

    Article  Google Scholar 

  13. Kolb HJ, Socie G, Duell T, Van Lint MT, Tichelli A, Apperley JF et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999; 131: 738–744.

    Article  CAS  Google Scholar 

  14. Morton LM, Saber W, Baker KS, Barrett AJ, Bhatia S, Engels EA et al. National Institutes of Health hematopoietic cell transplantation late effects initiative: the Subsequent Neoplasms Working Group Report. Biol Blood Marrow Transplant 2016; S1083-8791: 30331–30337.

    Google Scholar 

  15. Bhatia S, Francisco L, Carter A, Sun C-L, Baker KS, Gurney JG et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110: 3784–3792.

    Article  CAS  Google Scholar 

  16. Ehrhardt MJ, Brazauskas R, He W, Rizzo JD, Shaw BE . Survival of patients who develop solid tumors following hematopoietic stem cell transplantation. Bone Marrow Transplant 2016; 51: 83–88.

    Article  CAS  Google Scholar 

  17. Curtis RE, Metayer C, Rizzo JD, Socié G, Sobocinski KA, Flowers ME et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005; 105: 3802–3811.

    Article  CAS  Google Scholar 

  18. Wang Y, Brinch L, Jebsen P, Tanbo T, Kirschner R . A clinical study of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 747–753.

    Article  Google Scholar 

  19. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  Google Scholar 

  20. Inamoto Y, Shah NN, Savani BN, Shaw BE, Abraham AA, Ahmed IA et al. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant 2015; 50: 1013–1023.

    Article  CAS  Google Scholar 

  21. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 2012; 47: 337–341.

    Article  CAS  Google Scholar 

  22. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114–2119.

    Article  Google Scholar 

  23. Li Z, Mewawalla P, Stratton P, Yong ASM, Shaw BE, Hashmi S et al. Sexual health in hematopoietic stem cell transplant recipients. Cancer 2015; 121: 4124–4131.

    Article  Google Scholar 

  24. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012; 62: 147–172.

    Article  Google Scholar 

  25. Sri T, Merideth MA, Pulanic TK, Childs R, Stratton P . Human papillomavirus reactivation following treatment of genital graft-versus-host disease. Transpl Infect Dis 2013; 15: E148–E151.

    Article  CAS  Google Scholar 

  26. Aldabagh B, Angeles JGC, Cardones AR, Arron ST . Cutaneous squamous cell carcinoma and human papillomavirus: is there an association? Dermatol Surg 2013; 39: 1–23.

    Article  CAS  Google Scholar 

  27. Braaten KP, Laufer MR . Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol 2008; 1: 2–10.

    PubMed  PubMed Central  Google Scholar 

  28. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD . Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423–428.

    Article  CAS  Google Scholar 

  29. Ault KA . Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol 2006; 2006 (Suppl): 40470.

    PubMed  PubMed Central  Google Scholar 

  30. Ringdén O, Brazauskas R, Wang Z, Ahmed I, Atsuta Y, Buchbinder D et al. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transplant 2014; 20: 1777–1784.

    Article  Google Scholar 

  31. Moscicki A-B, Schiffman M, Kjaer S, Villa LL . Updating the natural history of HPV and anogenital cancer. Vaccine 2006; 24: S42–S51.

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported by Intramural Program of National Institutes of Health, NIH Clinical Center, National Heart, Lung and Blood Institute, and Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P Stratton.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shanis, D., Anandi, P., Grant, C. et al. Risks factors and timing of genital human papillomavirus (HPV) infection in female stem cell transplant survivors: a longitudinal study. Bone Marrow Transplant 53, 78–83 (2018). https://doi.org/10.1038/bmt.2017.210

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.210

Search

Quick links